Table 3 Pseudoresistance effects: ASM use.

From: Seizure control in mono- and combination therapy in a cohort of patients with Idiopathic Generalized Epilepsy

ASM

Number of events of pseudoresistance n/N

VPA

7/26 (26.9%)

LEV

6/24 (25%)

LTG

5/12 (41.7%)

VPA + LEV

1/11 (9.1%)

  1. ASM antiseizure medication, n number of pseudoresistance events, N number of patients on the ASM.
Back to article page